Keith H. Crawford Email & Phone Number

Denver, Co, Us

Denver, Co, Us

Mercer Island, Washington, Us

Recruited to this Nautic Partners healthcare company as a key executive to support and promote CarepathRx’s end-to-end pharmacy solutions. CarepathRx provides clinical enterprise pharmacy solutions for hospitals and health systems, building patient-centered, clinically-integrated specialty pharmacy programs to improve clinical outcomes, drive cost savings—and achieve better patient health.CarepathRx transforms hospital pharmacy from a cost center into an active revenue generator through a powerful combination of technology, market-leading pharmacy services and wrap-around services.Solutions and Services include:Specialty pharmacy software / specialty pharmacy set-up and support / hospital home infusion / 340B program optimization / polypharmacy management / telepharmacy / medication therapy management / limited distribution drugs and payor access programs.

Lone Tree, Us

360Pharma provides transaction advisory and diligence support for private equity groups as they manage the acquisition process to include; due diligence, deal valuation & structuring, regulatory review, negotiations and transaction documentation. Focusing on the non-hospital/post-acute care sectors to include hospital/physician/home-based infusion, specialty pharmacy, 503A and 503B pharmacies, medical device, and distribution services. 360Pharma also provides structured leadership and strategic direction to guide several crucial areas of operations to assist start-up and growth-phase infusion & speicalty pharmacies, pharmaceutical & biotech manufacturer, medical device, and medical service companiesDrug & Medical Device Development & Preparation360Pharma provides boutique regulatory and product development consulting services for biologics, pharmaceuticals and medical devices. Services include drug preparation, review, and management. Dossier preparation, submission, registration and drug approval guidance; filing of submissions to include Pre-INDs, INDs, eINDs, 505(b)(1) & 505(b)(2), 510k, pre-submission briefing documents, and investigator’s brochures.

Plymouth Meeting, Pa, Us

Recruited to this Linden Capital Partners healthcare company to provide insight leadership, design thinking, and actionable direction that lead to operational distinction and the simultaneous optimization of company growth and profitability. Solara Medical Supplies was purchased by Adapt Health Jul/20 for $425M or ~12x EBITDA. Prior to being purchased by Adapt Health, Solara Medical Supplies was the largest independent provider of Continuous Glucose Monitors (CGMs) and Specialty Pharmacy drug products to patients with Type-1 and Type-2 diabetes in the United States. Solara was licensed in all 50 states to distribute and dispense CGMs and Specialty drug products from two specialty pharmacy and medical device distribution centers. Solara was URAC, CHAPS, and ACHC accredited and had contracts with all major manufacturers and commercial health plans.

Irving, Texas, Us

Recruited to this New Mountain Capital (NMC) healthcare distribution, device, and technology company as a central member of the executive leadership team - to provide insight leadership to position Medical Speiclaty Distributors (MSD) to gain full consideration from potential buyside targets. Led the sell side transaction - MSD was acquired by McKesson Corporation for $800M (18x EBITDA) June 1, 2018MSD is a leading non-hospital/post-acute patient supply-chain solutions provider in the United States, providing products, distribution services, biomedical services, and technology solutions to the Home Infusion, Specialty & Institutional Pharmacies, Home Medical Equipment, and Oncology markets. 503A & 503B pharmacies - MSD is a recognized leader in cleanroom consumables supply chain. Our portfolio of products/supplies and guidance helps to ensure our pharmacy customers meet USP 795/797/800 and cGMP requirements. Customers include, 503A institutional and home pharmacies as well as institutional and local/national 503B pharmacies.

Phoenix, Az, Us

Recruited to this Beecken Petty O'Keefe & Company home infusion company to lead the infusion book of business; providing disciplined leadership, strategic direction, and actionable insights to guide several crucial functions that lead to operational distinction and the simultaneous optimization of company growth and profitability. Preferred was acquired by CVS for $300M - 12X EBITDA. Preferred Homecare is a regionally accredited and leading provider of evidence-based infusion services designed to optimize therapeutic outcomes while controlling cost of care. Caring for patients through an established and well-dispersed service footprint of six full service 503A infusion pharmacies, one 340B contracted location, and four infusion suites.Offering a full complement of Core & Specialty infusion and Specialty injectable medications supported by comprehensive nursing services. Contracted to provide exclusive oncology compounding and 340B drug dispensing programs. Robust payor portfolio comprised of both public- and private sector payors to include several capitated programs.

Lone Tree, Us

360Pharma Labs is a Healthcare Product Development and the Intellectual Property (IP) management firm assisting clients in the administration of their patents, trademarks, copyrighted works, and trade secrets with a goal to execute on a financial strategy to selectively commercialize their IP assets into revenue streams. 360Pharma Labs exclusively focuses on enhancing innovation performance across the front-end of ideation, portfolio and pipeline management, new product development launch, value management, and back-end asset protection. 360Pharma Labs leverages its deep experience across all aspects of the innovation continuum providing business strategy, intelligence, analytics, product lifecycle management, change leadership, and intellectual property management.Along with a diverse client list, 360Pharma Labs is the product development and commercialization arm for 360Pharma.

Denver, Co, Us

Value Creation:Accelerated revenue by ~$1.1 billion and improved EBITDA by 200% making Coram one of the top preforming healthcare companies in the United States. Coram was purchased by CVS in January 2014 for 15X EBITDA or $2.2B - original investment in Coram was ~$375M. Stemming from successes in previous role and deep awareness of company’s business and marketplace influencers, accepted new position to provide decisive course of action to accelerate revenue/EBITDA growth and to shape corporate-wide understanding and critical response to the Patient Protection and Affordable Care Act (Healthcare Reform). Develop and built programs to improve hospital financial performance and improve patient outcomes, drive M&A/partnership opportunities, and cultivate and mature ACO offerings - all in the effort to support accelerated growth initiatives. Acted as the company's principal healthcare legislative strategist and spokesperson. Central focus was to enhance corporate visibility into policy developments in order to drive faster and more nuanced insight and analysis on how current or pending healthcare policy will/would impact Coram's accelerated growth strategies. Authored key industry white papers detailing Healthcare Reform, Accountable Care Organizations, Vertically Integrated Healthcare Delivery Systems, Valued-Based Purchasing, Bundled Payments, Health Information Exchange, and 340B Programs. Recognized as a healthcare subject matter expert and frequent symposium/conference speaker.

Denver, Co, Us

Recruited to this Blackstone Group Healthcare Company as a key executive to develop, implement, and manage internal and external strategic and tactical marketing across the entire service portfolio, including refining the value proposition and further developing key messages to be customer centric compromising maintenance of brand reputation, brand development, brand role, and tone of voice so they transversely resonate with the specific needs of our diverse customer segments. Brand portfolio worth >$1.5B. Manufacturing Affairs: Responsible for procurement/contracting >$350MM in drug product and >$90MM in indirect contracts. Leveraged spend to build valued-based alliances with leading biopharmaceutical and medical supplies manufacturers and distributors. Clinical Trials: Reversed multi-year operating losses—took 150% revenue target shortfall to 240% of goal. Drove $18MM in revenue, 400% improvement in EBITDA, built contract pipeline of $25MM, and created a trail transition commercial pipeline of $96MM+. By direction of the CEO and Board of Directors, assumed full strategic and P&L management responsibility for struggling clinical trials franchise. Held autonomous decision-making authority to lead, develop, and revise organizational structure to meet functional needs; ensure communication, reporting, and incentives aligned people and processes. Developed, implemented, monitored, and acted on key profitability metrics, and ensured profitability did not come at the cost of clinical quality.

Co-founder and Executive Vice President of Proventiv Therapeutics, a clinical-stage specialty pharmaceutical company focused on drug discovery and development (505(b)(1)), drug re-profiling (505(b)(2)), and product commercialization. Developed and advanced four clinical candidates and two novel antibody therapies directed to treat secondary hyperparathyroidism, metabolic bone disease, and hyperphosphatemia associated with chronic kidney disease - protected with 15 patents stemming from 22 IP filings. Created the framework for the company's innovative process, managed and directed the intellectual property portfolio and strategic assets (drafted multiple patent and investigational drug applications), and increased operational agility - oversaw the chemistry, manufacturing, and control (CMC) process. Following FDA’s acceptance of new drug application development plans, Proventiv Therapeutics was acquired by Cytochroma Inc., a Canadian specialty clinical-stage pharmaceutical company.

Paris, France, Fr

Recruited to Bone Care International by the Board of Directors to serve as a core senior management team member and key strategist in turnaround effort following a failed product launch subsequently collapsing the company’s share price from $19 to $1.25. Overarching strategic goal was to position the company for merger or acquisition. Positioned brand as preferred choice and increased brand equity and longevity through strategic partnerships with advocacy groups, research institutions, and key opinion leaders, created national speakers' bureau of 350+ brand advocates; and co-invented, wrote, and submitted two new-use patents. Expanded market potential from 350K to 6MM+ patients with successful launch of new oral drug indication. Negotiated favorable labeling with FDA, structured positive pricing, and reinforced launch message with Landmark Patient Registry Program providing insight into lead product's effectiveness in the “real-world” setting; recruited 200 physicians which drove a 400% increase in patient starts. Delivered 11 quarters of double-digit revenue growth, increased company valuation by $645M, and improved EBITDA by 200%. Bone Care was acquired by Genzyme Corporation at share price of $34 leading to a 2,600% shareholder value increase.

Master Of Business Administration, Healthcare Management (Underway)

Bachelor Of Science (Bs), Marketing Management